169 related articles for article (PubMed ID: 12220625)
1. Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase.
Gan Y; Mo Y; Johnston J; Lu J; Wientjes MG; Au JL
FEBS Lett; 2002 Sep; 527(1-3):10-4. PubMed ID: 12220625
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
[TBL] [Abstract][Full Text] [Related]
3. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
4. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss.
Ji HJ; Rha SY; Jeung HC; Yang SH; An SW; Chung HC
Breast Cancer Res Treat; 2005 Oct; 93(3):227-36. PubMed ID: 16132531
[TBL] [Abstract][Full Text] [Related]
5. Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment.
Gomez DE; Tejera AM; Olivero OA
Biochem Biophys Res Commun; 1998 May; 246(1):107-10. PubMed ID: 9600076
[TBL] [Abstract][Full Text] [Related]
6. [Suppression of alternative telomere lengthening in cancer cells with reverse transcriptase inhibitors].
Bondarev IE; Khavinson VK
Adv Gerontol; 2016; 29(2):218-221. PubMed ID: 28514537
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines.
Fujimori J; Matsuo T; Shimose S; Kubo T; Ishikawa M; Yasunaga Y; Ochi M
J Orthop Res; 2011 Nov; 29(11):1707-11. PubMed ID: 21590716
[TBL] [Abstract][Full Text] [Related]
8. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
9. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.
Yatabe N; Kyo S; Kondo S; Kanaya T; Wang Z; Maida Y; Takakura M; Nakamura M; Tanaka M; Inoue M
Cancer Gene Ther; 2002 Jul; 9(7):624-30. PubMed ID: 12082463
[TBL] [Abstract][Full Text] [Related]
10. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
11. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.
Gan Y; Lu J; Yeung BZ; Cottage CT; Wientjes MG; Au JL
AAPS J; 2015 Jan; 17(1):268-76. PubMed ID: 25425294
[TBL] [Abstract][Full Text] [Related]
13. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.
Izbicka E; Nishioka D; Marcell V; Raymond E; Davidson KK; Lawrence RA; Wheelhouse RT; Hurley LH; Wu RS; Von Hoff DD
Anticancer Drug Des; 1999 Aug; 14(4):355-65. PubMed ID: 10625928
[TBL] [Abstract][Full Text] [Related]
14. Telomerase inhibition alters telomere maintenance mechanisms in laryngeal squamous carcinoma cells.
Chen W; Chen SM; Yu Y; Xiao BK; Huang ZW; Tao ZZ
J Laryngol Otol; 2010 Jul; 124(7):778-83. PubMed ID: 20403221
[TBL] [Abstract][Full Text] [Related]
15. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
16. Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy.
Ji XM; Xie CH; Fang MH; Zhou FX; Zhang WJ; Zhang MS; Zhou YF
Acta Pharmacol Sin; 2006 Sep; 27(9):1185-91. PubMed ID: 16923339
[TBL] [Abstract][Full Text] [Related]
17. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells.
Napier CE; Veas LA; Kan CY; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; MacKenzie KL
Biochim Biophys Acta; 2010 Oct; 1803(10):1142-53. PubMed ID: 20619302
[TBL] [Abstract][Full Text] [Related]
18. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
19. Alternative lengthening of telomeres is induced by telomerase inhibitors in Barrett's esophageal cells.
Qin X; Qi B; Zhao B
Oncol Rep; 2013 Apr; 29(4):1399-404. PubMed ID: 23338150
[TBL] [Abstract][Full Text] [Related]
20. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit.
Bryan TM; Marusic L; Bacchetti S; Namba M; Reddel RR
Hum Mol Genet; 1997 Jun; 6(6):921-6. PubMed ID: 9175740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
